Alzheimer’s Drug Trial Reaches Final Milestone
Researchers have completed final visits for a 247-patient study testing if cortisol regulation impacts dementia progression.
Updated on Sept. 23, 2026 in Alzheimer’s
Live Poll
Are you confident that current medical research is effectively addressing the progression of Alzheimer's disease?
Actinogen Medical has concluded the final patient visit for its XanaMIA clinical trial, which investigates the efficacy of the drug Xanamem in Alzheimer's patients. The company now prepares to analyze data from the 36-week study with results expected in late 2026.
Why it matters
This trial explores whether controlling cortisol levels in the brain can potentially slow the progression of Alzheimer's disease. By targeting this stress hormone pathway, researchers are testing a novel approach to management that differs from treatments focusing solely on amyloid-beta plaques.
The XanaMIA trial is a 36-week study of 247 participants with an average age of 75, utilizing pTau181 biomarker testing for patient selection. Two-thirds of the cohort possess the ApoE4 genetic risk factor, and the primary assessment measures progression via the Clinical Dementia Rating scale.
The players
Actinogen Medical
An Australian biotechnology company focusing on the development of drugs to treat neurological conditions including Alzheimer's disease.
The details
The experimental drug Xanamem is designed to modulate cortisol, a hormone that may influence neurodegeneration in Alzheimer's patients. By administering a 10-milligram daily dose, investigators seek to determine if reducing brain cortisol levels can stabilize cognitive function over the 36-week trial period. The study compares this intervention against a placebo group to assess changes in disease progression.
Timeline
September 2026: Final patient visit completed.
36 weeks: Duration of the clinical study per participant.
November 2026: Expected release of topline trial results.
Health Landscape
This study reflects the current shift toward using specific blood-based pTau181 biomarkers to standardize patient enrollment in Alzheimer's research. It represents a departure from traditional diagnostic methods, aiming to refine how therapies are tested in genetically diverse populations.
If you are managing Alzheimer's or caring for someone with the condition, discuss the role of emerging cortisol-targeting therapies with your neurologist to understand how they differ from current standard-of-care medications. Always verify if experimental trial options are suitable based on specific genetic markers like ApoE4.
The takeaway
While results are not yet available, this study highlights the importance of biomarker-based screening in matching patients to experimental dementia treatments. Families should continue to monitor updates from their physician regarding new therapeutic classes that move beyond traditional plaque-clearing methods.
What happens next
Actinogen Medical is scheduled to release the topline results from the XanaMIA trial in November 2026.
Further reading
For more information on current treatment pathways and research developments, visit our Alzheimer’s section.
Live Poll
Are you confident that current medical research is effectively addressing the progression of Alzheimer's disease?
